Lan Huang

BeyondSpring Inc (NASDAQ: BYSI) is trading significantly lower Wednesday after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the plinabulin NDA for prevention of chemotherapy-induced neutropenia. The FDA issued the CRL...

BeyondSpring Inc (NASDAQ: BYSI) recently announced positive topline data from its DUBLIN-3 registrational trial in plinabulin in combination with docetaxel for the treatment of second and third line non-small cell lung cancer. The study showed survival benefits and side effect...